Interview with Dr. Girard Deciphers at ELCC 2023

Interview with Dr. Girard Deciphers at ELCC 2023

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.
“Recent Developments in Lung Cancer Research: Insights from ELCC 2023”

“Recent Developments in Lung Cancer Research: Insights from ELCC 2023”

Dr Paz-Ares: I think this meeting is a particularly relevant meeting for continuous education, where the different and relevant aspects of lung cancer diagnosis, treatment and so on are reviewed and updated compared to standard-of-care. On top of that, some new data are typically presented. A good highlight for the current conference this year were some data updating the CHECKMATE-816 trial, showing more mature data on the benefit of chemotherapy plus nivolumab compared to chemotherapy as a neoadjuvant treatment in early stage non-small cell lung cancer. Importantly, it was suggested that an inflammatory signature may be predictive of benefit from this combination. There were some other interesting data updating the APPLE trial suggesting that third-generation TKIs like osimertinib are a better alternative compared to first-generation and then sequentially third-generation at time of progression even if using a liquid biopsy. Of course, there were updates of some other studies, including the presentation of novel phase III trials. There were two negative trials. The RESILIENT non-small cell lung cancer trial showed that the experimental drug, liposomal irinotecan, is not any better as compared to topotecan. And secondly, the CONTACT-01 trial with the addition of cabozantinib to atezolizumab does not improve prognosis, compared to standard-of-care in relapse non-small cell lung cancer.
Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.
Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases  at 2023 EHA  

Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases  at 2023 EHA  

The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children's Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of research, including the prognostic factors for relapsed childhood acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol in China, the use of Blinatumomab for 14 days in combination with chemotherapy to achieve minimal residual disease (MRD) conversion in pediatric B-ALL patients, the integration of transcriptomic features to improve prognosis prediction in pediatric acute myeloid leukemia (AML) with KMT2A rearrangements, and the effective treatment of pediatric non-sickle cell anemia (NSAA) with Hydroxyurea in combination with CSA. To gain a deeper understanding of these studies, Dr. Zhu has provided interpretations of the research findings, which are summarized below.
Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

The annual European Hematology Association (EHA) conference was recently held in Frankfurt, Germany, in a hybrid online and offline format. As the largest international conference in the European hematology field, the EHA meeting covered a wide range of scientific topics, clinical and basic research, including benign and malignant hematology, discussing the latest developments in the field of hematology. At this EHA conference, a study (abstract S224) by the team of Professor Ryan Jacobs from the Atrium Health Levine Cancer Institute in the U.S. explored the value of TNB-486 (targeting CD19/CD3) in the treatment of relapsed/refractory follicular lymphoma and achieved impressive results. As a result, Oncology Frontier interviewed Professor Ryan Jacobs on-site for a detailed interpretation of the latest developments in the treatment of follicular lymphoma and diffuse large B-cell lymphoma.
Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia

Dr. Peihua Lu: Targeting CD7 CAR-T Cells Holds Promise for Treating Central Nervous System T-Cell Lymphoblastic Lymphoma/Leukemia

T-cell lymphoblastic lymphoma (T-LBL) is a highly malignant and rare lymphoma with aggressive behavior. It primarily affects adolescents, often presenting with mediastinal lymph node enlargement and commonly accompanied by pericardial and pleural effusions. In some cases, the disease can involve the central nervous system (CNS) with neurological manifestations. About 20% of patients progress to acute T-cell lymphoblastic leukemia (T-ALL) in advanced stages, which has a rapid progression and poor prognosis.
Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology and discussing the latest advances in hematology. In the treatment of acute lymphoblastic leukemia (ALL), there was significant progress made at this EHA meeting, mainly focused on immunotherapy. To further grasp the content in this area, Oncology Frontier interviewed Professor Ma Jun from the Harbin Institute of Hematology & Oncology and discussed this topic in detail.